The data might be great but without financing/revenue they won't be able to complete the trials. I'm waiting to see how the revenue looks from all the new drug licenses they acquired.
I agree with your opinion, and am accumulating as much as I can month by month. I look forward to seeing the Phase 2/3 study results from Mexico. Last PR indicates that they are currently enrolling patients for the study. Harvard results will only add to verification of what could be some very positive results.
News 
Market Data 
Discover 
